Peptides DB
Research-centric peptide and protocol reference hub
Study 14 of 15Bofanglutide literatureGenes & diseases · Review2026

Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.

Precision nutritional oncology could potentially enhance cancer treatment by targeting metabolic interactions, but further research is needed to validate these concepts in clinical settings.

Read at Genes & diseasesAdd to compare

Where it sits

this study against the rest of the bofanglutide corpus
5
Preclinical
4
Observational
0
Open-label
2
Randomised
4
Reviews · this one

Summary and findings

This review explores the metabolic interactions between host and tumor environments, emphasizing the role of diet-induced metabolic shifts in cancer progression. It proposes a precision nutritional oncology paradigm using multi-omic biomarkers to track metabolic changes. The review highlights the potential of integrating precision nutrition into oncologic care to exploit tumor vulnerabilities.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2026

Abstract

The authors’ words, as Genes & diseases supplied them

Beyond somatic initiation, cancer progression is governed by a multidimensional systemic metabolic architecture. This permissive macroenvironment, shaped by systemic nutrient fluxes, endocrine networks, and microbial co-metabolites, sustains tumor bioenergetics and immune evasion. Bridging the current translational gap requires decoding the spatiotemporal reciprocity between diet-induced metabolic shifts, tumor microenvironment plasticity, and genotoxic therapy responses. In this review, we deconstruct the host-tumor metabolic interface through a systems biology framework, tracing the biotransformation of macro-dietary inputs into subcellular oncogenic and immunological signals. We move beyond traditional nutritional epidemiology to define a precision nutritional oncology paradigm that leverages high-resolution multi-omic biomarkers to track real-time systemic flux, the spatial ecosystem of the microbiome as a localized metabolic bioreactor, and context-dependent metabolic regulation to exploit transient tumor vulnerabilities. We emphasize the need for precise spatiotemporal calibration, particularly during acute refeeding windows, to prevent paradoxical therapy resistance or accelerated cachexia. Finally, we envision a future in which precision nutrition is seamlessly integrated into oncologic care, powered by artificial intelligence and digital gut twins for <i>in silico</i> modeling. By incorporating the broader chemical exposome and addressing structural socioeconomic determinants through frameworks such as the Planetary Health Diet, we outline a roadmap toward global health equity and enhanced metabolic resilience in cancer survivorship.

Background

Cancer progression is not solely driven by genetic mutations but also by complex systemic metabolic interactions. Understanding these interactions is crucial for developing precision nutritional strategies in oncology. This study addresses the need to decode the metabolic interface between host and tumor to improve cancer treatment outcomes.

Methods

This is a review article that utilizes a systems biology framework to analyze existing literature on the metabolic interactions between diet, tumor microenvironment, and cancer therapy responses. It does not involve new experimental data or specific study populations.

Results

The review identifies the role of systemic nutrient fluxes and endocrine networks in sustaining tumor bioenergetics and immune evasion. It suggests that precision nutrition, guided by multi-omic biomarkers, could exploit transient tumor vulnerabilities and improve cancer care.

Interpretation

The review builds on existing knowledge by proposing a novel framework for precision nutritional oncology. However, the lack of new experimental data limits the ability to assess the clinical significance of the proposed strategies. The integration of precision nutrition into cancer care remains theoretical at this stage.

Key findings

  • Cancer progression is influenced by systemic nutrient fluxes and endocrine networks.
  • The tumor microenvironment is shaped by diet-induced metabolic shifts.
  • Multi-omic biomarkers can track real-time systemic metabolic flux.
  • Precision nutrition could prevent therapy resistance or cachexia.
  • Artificial intelligence and digital gut twins may aid in modeling metabolic interactions.

Limitations

  • No new experimental data provided
  • Relies on existing literature and theoretical models
  • Lacks quantitative findings
  • Proposals remain theoretical

Elsewhere in the Bofanglutide corpus

DBridging Biosynthesis and Bioavailability: Integrated Strategies for Tailoring Soybean Isoflavone Profiles.Comprehensive reviews in food science and food safety · 2026reviewDOne Health implementation for rabies elimination in India by 2030: Progress, governance, challenges, and policy alignment.One health (Amsterdam, Netherlands) · 2026reviewCA Ready-to-Use Recombinant Yeast Two-Hybrid Assay for Thyroxine Detection.Biosensors · 2026 · EC50 values ranged from 350 nM to 550 nM for thyroxine.In vitroCFe(III)-(II) Mineral Transformation and Associated Organic Matter Stabilization Processes in a Tidal Marsh Soil.Environmental science & technology · 2026 · Not reported in abstract.In vitroBGlobal, regional, and national burden of HIV/AIDS, 1990-2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023.The lancet. HIV · 2026 · 2.06 million new HIV infections globally in 2023 (1.88-2.29 million).reviewAAssessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease.Circulation. Population health and outcomes · 2023 · n=3405 · Each 5-point increase in the current SAQ-SS was associated with a 7% lower risk of the primary endpoint (hazard ratio, 0.93 [95% CI, 0.90-0.96]).Human